paroxetine has been researched along with citalopram in 347 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (3.46) | 18.7374 |
| 1990's | 57 (16.43) | 18.2507 |
| 2000's | 137 (39.48) | 29.6817 |
| 2010's | 115 (33.14) | 24.3611 |
| 2020's | 26 (7.49) | 2.80 |
| Authors | Studies |
|---|---|
| Costanzo, MJ; Maryanoff, BE; McComsey, DF; Nortey, SO; Shank, RP; Vaught, JL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Chi, DY; Choe, YS; Chu, S; Jeong, KJ; Jin, C; Lee, BC; Lee, BS | 1 |
| Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ben-Daniel, R; Brust, P; Deuther-Conrad, W; Mishani, E; Scheunemann, M; Steinbach, J | 1 |
| Brust, P; Deuther-Conrad, W; Fischer, S; Funke, U; Hiller, A; Scheunemann, M; Steinbach, J | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bojarski, AJ; Bugno, R; Duszyńska, B; Hogendorf, A; Hogendorf, AS; Kurczab, R; Lenda, T; Pietruś, W; Satała, G; Staroń, J; Wantuch, A; Warszycki, D | 1 |
| Crewe, HK; Haddock, RE; Lennard, MS; Tucker, GT; Woods, FR | 1 |
| Mellerup, ET; Plenge, P | 2 |
| Laursen, H; Mellerup, ET; Plenge, P | 2 |
| Bengtsson, BO; Lundmark, J; Wålinder, J | 1 |
| Insel, TR; Winslow, JT | 1 |
| Mellerup, ET; Nielsen, M; Plenge, P | 1 |
| Blier, P; Galzin, AM; Langer, SZ | 1 |
| Bäckström, I; Bergström, M; Marcusson, J | 1 |
| Andersson, A; Bäckström, I; Marcusson, JO | 1 |
| Esnaud, H; Graham, D; Habert, E; Langer, SZ | 1 |
| Galzin, AM; Langer, SZ; Moret, C; Verzier, B | 1 |
| Koshikawa, F; Koshikawa, N; Stephenson, JD | 1 |
| Fuller, RW | 1 |
| Asberg, M; Eriksson, B; Mårtensson, B; Träskman-Bendz, L; Wägner, A | 1 |
| Briley, M; Moret, C | 1 |
| Graham, D; Langer, SZ; Tahraoui, L | 1 |
| Bergström, M; Eriksson, K; Marcusson, JO; Ross, SB | 1 |
| Eriksson, K; Marcusson, J | 1 |
| Erreboe, I; Mellerup, ET; Plenge, P | 1 |
| Baumann, P; Rochat, B | 1 |
| Hyttel, J; Sánchez, C | 1 |
| Gobbi, M; Mennini, T; Palacios, JM; Pompeiano, M; Regondi, MC | 1 |
| Asou, T; Hayashida, M; Minami, H; Nakane, Y; Tateishi, T; Togita, M; Tsujimura, T | 1 |
| Falkowski, J; Horton, RW; Jacobson, RR; Lawrence, KM | 1 |
| Arranz, B; Marcusson, J | 1 |
| Auerbach, SB; Hjorth, S | 2 |
| Brøsen, K | 1 |
| Buchholtz-Hansen, PE; Kragh-Sørensen, P; Wang, AG | 1 |
| Bolwig, TG; Dam, H; Mellerup, ET; Plenge, P | 1 |
| Chiba, K; Ishizaki, T; Kobayashi, K; Kuroiwa, Y; Tani, M; Yamamoto, T | 1 |
| Brøsen, K; Gram, LF; Jeppesen, U; Loft, S; Poulsen, HE; Vistisen, K | 1 |
| Harnett-Sheehan, K; Sheehan, DV | 1 |
| Baumann, P; Eap, CB | 1 |
| Fischer, P; Goessler, R; Kasper, S; Vesely, C | 1 |
| Hayashi-Kuwabara, Y; Ikeda, Y; Izumi, J; Kiuchi, Y; Oguchi, K; Tanaka, Y; Washizuka, M; Yoshinaga, K | 1 |
| Meier, E; Sánchez, C | 1 |
| Earley, B; Faherty, CJ; Leonard, BE | 1 |
| Artigas, F; Romero, L | 1 |
| al-Tikriti, M; Baldwin, RM; Innis, RB; Schaus, JM; Soufer, R; Stratton, MD; Zea-Ponce, Y | 1 |
| Bellodi, L; Bianchi, L; Mundo, E | 1 |
| Stein, MB | 1 |
| Amey, M; Baumann, P; Bouchoux, G; Cochard, N; Eap, CB; Savary, L | 1 |
| Belpaire, FM; Brøsen, K; Rasmussen, BB; Temmerman, A; Wijnant, P | 1 |
| Baldwin, DS; Birtwistle, J | 1 |
| Bourin, M; Redrobe, JP | 1 |
| Barbey, JT; Roose, SP | 1 |
| Gram, LF | 1 |
| Stahl, SM | 1 |
| Agren, H; Björling, G; Fahlén, T; Landén, M | 1 |
| Dekeyne, A; Girardon, S; Gobert, A; Millan, MJ | 1 |
| Anand, VS; Dewan, MJ | 1 |
| Harkin, A; Kelly, JP; Leonard, BE; Redmond, AM | 1 |
| Blier, P; de Montigny, C; Szabo, ST | 1 |
| De Vry, J; Maurel, S; Schreiber, R | 1 |
| Agren, H; Eriksson, E; Fahlén, T; Landén, M | 1 |
| Kristensen, AS; Mortensen, OV; Rudnick, G; Wiborg, O | 1 |
| Thompson, C | 1 |
| Nutt, DJ | 1 |
| Rink, J; Stein, DJ | 1 |
| Carleborg, L; Hägg, S; Ohman, R; Spigset, O | 1 |
| Bakker, A | 1 |
| Battaglia, G; Carroll, FI; Kuhar, MJ; Vicentic, A | 1 |
| Bauer-Wittmund, T; Müller, U; Murai, T; von Cramon, DY | 1 |
| Bugge, A; Kristoffersen, L; Lundanes, E; Slørdal, L | 1 |
| Härtter, S; Hiemke, C | 1 |
| Costentin, J; Leroux-Nicollet, I; Naudon, L; Raisman-Vozari, R; Vilpoux, C | 1 |
| Ashton, AK | 1 |
| Terao, T | 1 |
| Erazo, N; Greil, W; Grohmann, R; Horvath, A; Sassim, N | 1 |
| Blier, P; Culpepper, L; Gorman, JM; Hirschfeld, RM; Leon, AC; Nierenberg, AA; Roose, SP; Rosenbaum, JF; Stahl, SM; Trivedi, MH | 1 |
| Kaschka, WP; König, F; Neuhöffer-Weiss, M; Petersdorff, T; von Hippel, C; Wolfersdorf, M | 1 |
| Kremer, C; Quitkin, FM; Taylor, BP | 1 |
| Bellodi, L; Bertani, A; Caldirola, D; Perna, G; Smeraldi, E | 1 |
| Bergsholm, YK; Bøhler, E; Nordeng, H; Spigset, O | 1 |
| Bellodi, L; Cavallini, MC; Cavedini, P; Diaferia, G; Erzegovesi, S; Locatelli, M | 1 |
| Ginovart, N; Goulding, V; Hood, K; Houle, S; Hussey, D; Meyer, JH; Wilson, AA | 1 |
| Angulo, J; Cuevas, P; Gabancho, S; Gupta, S; Peiró, C; Sáenz de Tejada, I; Sanchez-Ferrer, CF | 1 |
| Olivier, B; Waldinger, MD; Zwinderman, AH | 1 |
| Greibrokk, T; Kristoffersen, L; Lundanes, E; Molander, P; Thomassen, A | 1 |
| Chu, S; Jin, C; Lee, BS; Se Lee, B; Song, YS; Yoon Chi, D | 1 |
| Barnes, NM; Blakely, RD; Bowery, NG; Chamba, A; Gordon, J; Grafton, G; Gregory, CD; Serafeim, A | 1 |
| Brown, EB; Gonzales, JS; Miner, CM; Munir, R | 1 |
| Cullen, N; Lexell, J; Zafonte, RD | 1 |
| Droogmans, G; Maertens, C; Nilius, B; Verbesselt, R | 1 |
| Bjørnholm, B; Elfving, B; Knudsen, GM | 1 |
| Ferguson, JM; Lydiard, RB; Thase, ME; Wilcox, CS | 1 |
| Harvey, BH; Rosenberg, R; Volke, V; Wegener, G | 1 |
| Barnes, NM; Bunce, CM; Chamba, A; Drayson, MT; Gordon, J; Grafton, G; Gregory, CD; Holder, MJ; Luong, QT; Serafeim, A | 1 |
| Chilton, AP; Elias, E; Hubscher, SG; Milkiewicz, P | 1 |
| Robbins, A | 1 |
| Anderson, TA; Dobscha, SK; Hauser, P; Hoffman, WF; Snodgrass, LS; Turner, EH; Winterbottom, LM | 1 |
| Downes, F; Isbister, GK; Whyte, IM | 1 |
| Altshuler, LL; Haynes, D; Hendrick, V; Hwang, S; Lee, E; Stowe, ZN | 1 |
| Bourin, M; Dailly, E; David, DJ; Hascoët, M; Ripoll, N | 1 |
| Bourin, M; David, DJ; Gardier, AM; Jego, G; Jolliet, P; Przybylski, C | 1 |
| Broocks, A; Hohagen, F; Kordon, A | 1 |
| Akin, A; Chaturvedi, AK | 1 |
| Angulo, J; Cuevas, B; Cuevas, P; Gupta, S; Sáenz de Tejada, I | 1 |
| Bateman, DN; Chick, J; Good, AM; Kelly, CA; Masterton, G | 1 |
| Almarza, E; Martínez, MA; Sánchez de la Torre, C | 1 |
| Carella, A; Cheok, A; Ginovart, N; Houle, S; Hussey, D; Meyer, JH; Potter, WZ; Sagrati, S; Spencer, EP; Wilson, AA | 1 |
| Cryan, JF; Dalvi, A; Friedland, JC; Hirsch, BR; Jin, SH; Lucki, I; O'Leary, OF; Ouyang, M; Page, ME; Thomas, SA | 1 |
| Brown, EB; Joliat, MJ; Miner, CM | 1 |
| Eichner, SF; Jones, JR; Moore, ML | 1 |
| Adrover, M; Bailey, JE; Nutt, DJ; Potokar, J; Rich, AS; Wilson, SJ | 1 |
| Armbrust, KL; Black, MC; Henry, TB; Kwon, JW | 1 |
| Albert, U; Bogetto, F; Maina, G; Salvi, V | 1 |
| Baldwin, DS; Bradley, BP; Brodrick, P; Mogg, K | 1 |
| Calviño, MA; Iscla, IR; Szczupak, L | 1 |
| Elfving, B; Wiborg, O | 1 |
| Högberg, P; Landén, M; Thase, ME | 1 |
| Argyropoulos, S; Hale, AS; Willner, P | 1 |
| Huande, L; Juan, H; Zhiling, Z | 1 |
| Harrison, D; Meng, F; Mullins, CD; Shaya, FT; Wang, J | 1 |
| Egberts, AC; Heerdink, ER; Hugtenburg, JG; van Geffen, EC; van Hulten, RP | 1 |
| Cyranowski, JM; Fagiolini, A; Frank, E; Kupfer, DJ; Scott, J; Shear, MK; Swartz, H | 1 |
| Andersen, EW; Lader, M; Stein, DJ | 1 |
| Bourin, M; Hascoët, M; Massé, F | 1 |
| Cantoni, A; Fontò, S; Giannelli, MR; Maggini, C; Marchesi, C | 2 |
| Kozian, R | 1 |
| Langman, NJ; Smith, CG; Whitehead, KJ | 1 |
| Fava, M; Mallinckrodt, CH; Martinez, JM; Prakash, A; Watkin, JG; Wohlreich, MM | 1 |
| Carrasco, JL; Sandner, C | 1 |
| Arias, B; Catalán, R; Fañanás, L; Gastó, C; Lorenzi, C; Serretti, A | 1 |
| Baldwin, DS; Lader, M; Montgomery, SA; Nil, R | 1 |
| Lang, AE; Voon, V | 1 |
| Benturquia, N; Haddjeri, N; Mansari, ME; Mnie-Filali, O; Sánchez, C; Wiborg, O | 1 |
| Abraham, G; Milev, R; Stuart Lawson, J | 1 |
| Albertazzi, P | 1 |
| Baldwin, DS; Cooper, JA; Hindmarch, I; Huusom, AK | 1 |
| Berger, U; Jensen, E; Kallenborn, R; Samuelsen, PJ; Vasskog, T | 1 |
| Hogg, S; Jessa, M; Michan, L | 1 |
| Bron, MS; Meng, F; Mullins, CD; Shaya, FT; Wang, J | 1 |
| Bourin, M; Chenu, F; Dailly, E | 1 |
| Bourin, M; Chenu, F; Gardier, AM; Guiard, BP | 1 |
| Baekdal, T; Boulenger, JP; Florea, I; Huusom, AK; Sarchiapone, M | 1 |
| Baldwin, DS; Huusom, AK; Maehlum, E | 1 |
| Greenhill, LL; Moreno, C; Roche, AM | 1 |
| Ayestarán, A; Carrera, M; García-Unzueta, MT; Herrán, A; Hoyuela, F; Ramírez, ML; Rodríguez-Cabo, B; Sierra-Biddle, D; Vázquez-Barquero, JL | 1 |
| Baldwin, DS; Despiegel, N; Drost, PB; Hemels, ME; Jørgensen, TR; Stein, DJ | 1 |
| Bailly, D | 1 |
| Haro, JM; Peñarrubia, MT; Pinto-Meza, A; Serrano-Blanco, A; Suárez, D | 1 |
| Ashby, CR; Blackburn, TP; Ramachandran, PV; Sekine, Y; Suzuki, K | 1 |
| Alexander, IM; Moore, A | 1 |
| Andersen, EW; Fineberg, N; Stein, DJ; Tonnoir, B | 1 |
| Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
| Gether, U; Plenge, P; Rasmussen, SG | 1 |
| Detke, MJ; Faries, DE; Mallinckrodt, CH; Meyers, AL; Prakash, A | 1 |
| Andrews, AM; Chenu, F; David, DJ; Deltheil, T; Gardier, AM; Guiard, BP; Hamon, M; Hen, R; Lanfumey, L; Le Maître, E; Leroux-Nicollet, I; Renoir, T; Sokoloff, P | 1 |
| Alacqua, M; Arcoraci, V; Calarese, T; Di Vita, G; Gagliano, C; Germanò, E; Magazù, A; Spina, E; Trifirò, G | 1 |
| Hetrick, S; McKenzie, J; Merry, S; Proctor, M; Sindahl, P | 1 |
| Bogetto, F; Crespi, C; Maina, G; Rosso, G | 1 |
| Drago, F; Leggio, GM; Micale, V | 1 |
| Altunayoglu, V; Boz, C; Gazioglu, S; Hocaoglu, C | 1 |
| Bekele, NB; Shih, YC; Xu, Y | 1 |
| Benattia, I; Demitrack, M; Entsuah, R; Nemeroff, CB; Sloan, DM; Thase, ME | 1 |
| Busto, G; Di Spigno, D; Falcini, R; Salvati, L; Tundo, A | 1 |
| Benmansour, S; Coudoré, F; David, DJ; Deloménie, C; Deltheil, T; Gardier, AM; Guiard, BP; Guilloux, JP; Le Maitre, E; Leroux-Nicollet, I; Nicolas, L; Repérant, C | 1 |
| Detke, MJ; Fava, M; Houston, JP; Mallinckrodt, CH; Prakash, A; Swindle, R | 1 |
| Cantoni, A; De Panfilis, C; Giannelli, MR; Maggini, C; Marchesi, C | 1 |
| Alexander, T; Ances, BM; Ellis, RJ; Letendre, SL | 1 |
| Abebe, K; Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, G; Hughes, C; Iyengar, S; Keller, M; Kennard, B; Leonard, H; McCracken, J; Melhem, N; Onorato, M; Porta, G; Ritz, L; Ryan, N; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD; Zelazny, J | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
| Bereza, BG; Einarson, TR; Iskedjian, M; Le Melledo, JM; Walker, JH | 1 |
| Aperi, J; Borenstein, J; Jones, JB; Karne, A; Shah, NR; Shemtov, R | 1 |
| Brennum, LT; Kreilgaard, M; Sánchez, C; Smith, DG | 1 |
| Andersen, EW; Carey, PD; Fineberg, N; Lochner, C; Seedat, S; Stein, DJ | 1 |
| Pinhasov, A; Rehavi, M; Reichenstein, M | 1 |
| Crowley, JJ; Hill, TI; Hoshaw, BA; Khawaja, X; Lucki, I; Malberg, JE; Rosenzweig-Lipson, S; Schechter, LE | 1 |
| Kim, YK; Lee, HY | 1 |
| Andersen, HF; Kilts, CD; Schlaepfer, TE; Wade, AG | 1 |
| Dotan, Y; Pillar, G; Suraiya, S | 1 |
| Baldwin, DS; Boulenger, JP; Kasper, S; Larsson Lönn, S | 1 |
| Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J | 1 |
| David, DJ; Deltheil, T; Gardier, AM; Hen, R; Reperant, C; Tanaka, K | 1 |
| Davidson, S; Gil-Ad, I; Harell, D; Maayan, R; Prokonov, D; Taler, M; Weizman, A | 1 |
| Imai, T; Inoue, K; Nagata, K; Tozaki-Saitoh, H; Tsuda, M; Yamashita, T | 1 |
| Spadone, C | 1 |
| Croghan, TW; Daniel, G; Erder, MH; Esposito, D; Stoto, MA; Wahl, P | 1 |
| Gale, CK; Millichamp, J | 1 |
| Aznar, S; Knudsen, GM; Licht, CL; Marcussen, AB; Overstreet, DH; Wegener, G | 1 |
| Carrilho, E; Catai, AP; Lanças, FM; Queiroz, ME | 1 |
| Bertoletti, E; Chilovi, BV; Conti, M; Padovani, A; Rozzini, L; Trabucchi, M; Zanetti, M | 1 |
| Huhtala, H; Illi, A; Kampman, O; Lehtimäki, T; Leinonen, E; Mononen, N; Poutanen, O; Setälä-Soikkeli, E; Viikki, M | 1 |
| De Koning, FH; Derijks, HJ; Egberts, AC; Heerdink, ER; Janknegt, R; Krekels, MM; Looij, BJ | 1 |
| Anderssen, T; Bergersen, O; Eggen, T; Jensen, E; Vasskog, T | 1 |
| Lanza di Scalea, T; Wisner, KL | 1 |
| Brent, DA | 1 |
| Boulenger, JP; Hermes, A; Huusom, AK; Weiller, E | 1 |
| Drummer, OH; Gerostamoulos, D; Pilgrim, JL | 1 |
| Charles, D; Fava, M; Papakostas, GI | 1 |
| Dormuth, CR; Lee, JC; Mehta, J; Miller, M; Patrick, AR; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Dormuth, C; Lee, JC; Mehta, J; Miller, M; Patrick, AR; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Fineberg, NA; Hollander, E; Legault, M; Marteau, F; Stein, DJ | 1 |
| Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P | 1 |
| Krass, M; Rünkorg, K; Volke, V; Wegener, G | 1 |
| Mochcovitch, MD; Nardi, AE | 1 |
| Antonioli, L; Blandizzi, C; Colucci, R; Corona, T; Fornai, M; Mantarro, S; Montagnani, S; Pergola, A; Ruggiero, E; Scollo, C; Testi, A; Tuccori, M | 1 |
| Aprile, S; Cabrino, C; De Panfilis, C; Marchesi, C; Parenti, P | 1 |
| Kaneko, S; Kitagawa, Y; Kitaichi, M; Nagayasu, K; Nakagawa, T; Shirakawa, H; Yatani, Y | 1 |
| Deshpande, A; Ing, A; Rizo, C; Seeman, N | 1 |
| Choi, HC; Kang, TC; Kim, DS; Kim, JE; Kim, YI; Song, HK | 1 |
| Hannestad, J | 1 |
| Dobzhenko, MN; Shchepotin, IB; Zotov, AS | 1 |
| Chauvet-Gélinier, JC | 1 |
| Appiani, F; Carroll, BT; Muñoz, C; Trecco, J | 1 |
| Beste, J; Blackwell, JC; Patel, BN | 1 |
| Kulikov, AV; Kulikov, VA; Osipova, DV; Popova, NK; Tikhonova, MA | 1 |
| Abe, T; Hirano, J; Kashima, H; Mimura, M; Nakajima, S; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K; Yagihashi, T | 1 |
| Dasgupta, K; Labos, C; Nedjar, H; Rahme, E; Turecki, G | 1 |
| Chamielec, M; Gałecki, P; Talarowska, M; Zboralski, K | 1 |
| Balhara, YP; Deshpande, SN; Verma, R | 1 |
| Knapp, LE; Miceli, JJ; Ramey, TS; Rickels, K; Shiovitz, TM; Weaver, JJ | 1 |
| Mandrioli, R; Mercolini, L; Raggi, MA; Saracino, MA | 1 |
| Blakely, RD; Bonnin, A; Levitt, P; Zhang, L | 1 |
| Gotzlav, Y; Iancu, I; Kertzman, S; Kotler, M; Reznik, I; Vainder, M; Weizman, A | 1 |
| Adriaansen, HJ; De Groot, PG; Jansen, C; Naarding, P; Remijn, JA; Riphagen, J; Roest, M; Van Holten, TC | 1 |
| Jun, IG; Kim, SH; Lee, BS; Park, JY | 1 |
| Cortés, JM; Hidalgo, M; Jönsson, JÅ; Larsson, E; Sagristà, E; Salvadó, V | 1 |
| Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M | 1 |
| Barbui, C; Churchill, R; Cipriani, A; Furukawa, TA; Imperadore, G; Purgato, M; Signoretti, A; Trespidi, C; Watanabe, N | 1 |
| Holsboer, F; Perisic, T; Rein, T; Yu, S; Zimmermann, N; Zschocke, J | 1 |
| Canovi, M; Dallanoce, C; De Amici, M; De Micheli, C; Gobbi, M; Matera, C; Mennini, T | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C | 1 |
| Choi, SJ; Hahn, SJ; Hong, YJ; Kim, HJ; Kim, TH; Rhie, DJ; Sung, KW; Yang, JS; Yoon, SH | 1 |
| Beeské, S; Griebel, G; Stahl, SM | 1 |
| Cox, GR; Hetrick, SE; McKenzie, JE; Merry, SN; Simmons, MB | 1 |
| Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE | 1 |
| Campos-Torres, A; Haase, J; Malynn, S; Moynagh, P | 1 |
| Gorman, DA; Lam, D; Patten, S; Pringsheim, T | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, GN; Emslie, GJ; He, J; Hilton, RC; Keller, MB; Mansoor, B; Mayes, T; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Berk, M; Dodd, S; Kelin, K; Mancini, M; Schacht, A | 1 |
| Chang, LH; Chen, CH; Hsiao, CF; Hsiao, MC; Hsu, YT; Lai, HL; Lin, HL; Lin, KM; Lin, PS; Liu, CY; Liu, SI; Liu, YL; Shen, WW; Tang, HS; Tsou, HH | 1 |
| Park, YM | 1 |
| Birmaher, B; Brent, D; Clarke, G; Emslie, GJ; He, J; Hilton, R; Mansoor, B; Mayes, TL; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Spirito, A; Wagner, KD | 1 |
| Bishop, C; Conti, MM; Dell'isola, R; Goldenberg, AA; Kampton, E; Katzman, AC; Lindenbach, D; Ostock, CY | 1 |
| Hou, XJ; Wang, J; Xu, JH; Yu, YY | 1 |
| Cho, HY; Kim, JE; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Seo, MK; Seol, W | 1 |
| Seyfried, CA; van Amsterdam, C | 1 |
| Montgomery, SA; Reines, EH; Sanchez, C | 1 |
| Bundeff, AW; Woodis, CB | 1 |
| Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T | 1 |
| Handley, AP; Williams, M | 1 |
| Becker, T; Koesters, M; Ma, Y; Zhang, Y | 1 |
| IsHak, WW; Karamians, R; Peselow, ED; Pizano, D; Tobia, G | 1 |
| Hermann, M; Molden, E; Waade, RB | 1 |
| Cobb, T; Haswell, D; Hodgman, M; Martini, DI; Nacca, N | 1 |
| Dueñas, H; Haro, JM; Hong, J; Moneta, MV; Montgomery, W; Novick, D; Peng, X | 1 |
| Benetti, F; Blandina, P; Cassano, T; Corradetti, R; Galeotti, N; Munari, L; Passani, MB; Provensi, G | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N | 1 |
| Banzi, R; Cusi, C; Moja, L; Randazzo, C; Sterzi, R; Tedesco, D | 1 |
| Cantrell, SE; Häuser, W; Nishishinya, MB; Urrútia, G; Walitt, B | 1 |
| Dursun, AE; Koçer, A; Koçer, E; Krpnar, İ; Özsütçü, M | 1 |
| Halling-Sørensen, B; Hansen, CH; Jacobsen, NW; Nellemann, C; Styrishave, B | 1 |
| Beaulieu, JM; Chahine, M; Poulin, H; Thériault, O | 1 |
| Patterson, B; Van Ameringen, M | 1 |
| Egashira, N; Kuwahara, J; Masuda, S; Ueda, M; Ushio, S; Yamada, T; Zukeyama, N | 1 |
| Bannink, M; Binkhorst, L; de Bruijn, P; den Boer, TD; Droogendijk, H; Jager, A; Lam, MH; Mathijssen, RH; Ruit, J; van Alphen, RJ; van Gelder, T | 1 |
| Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL | 1 |
| Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A | 1 |
| Barlow, DH; Farchione, TJ; Gallagher, MW; Gorman, JM; Payne, LA; Shear, MK; White, KS; Woods, SW | 1 |
| Banerjee, P; Chan, JS; Choi, YK; Olivier, B; Oosting, RS; Tarazi, F | 1 |
| Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K | 1 |
| Coleman, JA; Gouaux, E; Green, EM | 1 |
| Arakawa, R; Kim, W; Ogawa, K; Okubo, Y; Sakayori, T; Tateno, A | 1 |
| Andreão, RV; Benseñor, IM; Bittencourt, MS; Brunoni, AR; Dantas, EM; Fráguas, R; Kemp, AH; Koenig, J; Lotufo, PA; Mill, JG; Nunes, MA; Ribeiro, AL; Thayer, JF | 1 |
| Eriksson, E; Hieronymus, F; Nilsson, S | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Li, Y; Lu, X; Tao, C; Yan, W | 1 |
| Chen, J; Deng, X; Fang, L; Lei, T; Lei, Y; Qu, Z; Zhang, L; Zhao, X; Zhong, J; Zhou, C; Zou, B | 1 |
| Casavant, MJ; Chounthirath, T; Russell, JL; Spiller, HA | 1 |
| Brekke, M; Molden, E; Skogvoll, E; Spigset, O; Westin, AA | 1 |
| Araujo, M; Benevent, J; Bondon-Guitton, E; Chebane, L; Durrieu, G; Montastruc, F; Montastruc, JL; Ojero-Senard, A | 1 |
| Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C | 1 |
| Chen, XF; Gao, NN; Jin, ZL; Li, XR; Li, YF; Ran, YH; Xiong, J; Zheng, YY | 1 |
| Emilsson, JF; Eriksson, E; Hieronymus, F; Lisinski, A; Näslund, J; Nilsson, S | 1 |
| Eltonsi, TK; GamalEl Din, SF; Mahmoud, MA; Rashed, LA; Tawfik, TM | 1 |
| Andersen, J; Bang-Andersen, B; Rannversson, H; Strømgaard, K | 1 |
| Agius, M; Ripullone, K; Womersley, K | 1 |
| Eriksson, E; Hieronymus, F; Lisinski, A; Nilsson, S | 3 |
| Bahar, MA; Bos, JHJ; Hak, E; Wang, Y; Wilffert, B | 1 |
| Bogdanova, OV; D'Anci, KE; Kanekar, S; Olson, PR; Ombach, HJ; Petersen, M; Renshaw, CE; Renshaw, PF; Sheth, CS; Sung, YH | 1 |
| Carleton, BC; Etminan, M; Guo, MY; Kezouh, A; Kim, DD; Procyshyn, RM; Samii, A | 1 |
| Gao, YL; He, B | 1 |
| Christensen, MC; McIntyre, RS; Sluth, LB | 1 |
| Croarkin, PE; Mills, JA; Strawn, JR | 1 |
| Aitchison, KJ; Binder, EB; Carrillo-Roa, T; Cattaneo, A; DeModena, A; Henigsberg, N; Kelsoe, JR; Leckband, SG; Liu, JJ; McCarthy, M; Mors, O; Ren, H; Rietschel, M; Shekhtman, T; Wei, YB | 1 |
| Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S | 1 |
| Barbui, C; Bennie, M; Godman, B; Hurding, S; Johnson, CF; Kurdi, A; Leporowski, A; MacBride-Stewart, S; McCabe, H; Morton, A | 1 |
| Arnold, PD; Bousman, C; Greenslade, A; Maruf, AA | 1 |
| Chen, L; Cheng, S; Guo, S; Xu, H | 1 |
| Alag, P; Balasubramaniam, M; Gupta, A; Gupta, S; Joshi, P; Maher, S; Tampi, D; Tampi, RR; Young, J | 1 |
| Doucet, N; Hudon Thibeault, AA; López de Los Santos, Y; Sanderson, JT; Vaillancourt, C | 1 |
| Holper, L | 1 |
| Blanco, C; Fagot-Campagna, A; Fossati, P; Goldberg, M; Haffen, E; Hoertel, N; Lemogne, C; Limosin, F; Olekhnovitch, R; Olfson, M; Zins, M | 1 |
| Cabrera, RM; Kim, J; Law, E; Linda Lin, Y; Wlodarczyk, BJ | 1 |
| Liao, XM; Si, TM; Su, YA; Wang, Y; Yu, X | 1 |
| Furukawa, TA; Imai, H; Noma, H | 1 |
| Hui, A | 1 |
| Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM | 1 |
| Abbaszadegan, MR; Ahmadimanesh, M; Hedayati, N; Jamialahmadi, T; Sahebkar, A; Yazdian-Robati, R | 1 |
| Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V | 1 |
| Chen, L; Feng, X; Huang, C; Shen, X; Wang, J; Xu, T | 1 |
| Brouwer, JMJL; Buunk, AM; de Boer-Veger, NJ; Deneer, VHM; Guchelaar, HJ; Houwink, EJF; Mulder, H; Nijenhuis, M; Rongen, GAPJM; Soree, B; Swen, JJ; van Schaik, RHN; van Westrhenen, R; Weide, JV; Wilffert, B | 1 |
| Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA | 1 |
| Camino, S; Godoy, A; Smith, J; Strejilevich, SA; Szmulewicz, A | 1 |
| Cipelli, R; Dell'Osso, B; Di Nicola, M; Martinotti, G; Peduto, I; Pugliese, AC; Signorelli, MS; Ventriglio, A | 1 |
| Giraldi, A; Hutters, CL | 1 |
| Bracke, F; Frieling, H; Leffler, A | 1 |
| Bannerman, DM; Collins, HM; Ozdemir, D; Pinacho, R; Sharp, T | 1 |
| Dunham, KE; Venton, BJ | 1 |
| Al-Khatib, SM; Assimon, MM; Brookhart, MA; Flythe, JE; Gaynes, BN; Pun, PH; Winkelmayer, WC | 1 |
| Acosta, A; Bielinski, SJ; Camilleri, M; Cifuentes, L; Decker, PA; Gonzalez-Izundegui, D; Hurtado, MD; Moyer, AM; Ricardo-Silgado, ML; Singh, S | 1 |
| Azoulay, L; Cao, TXD; Fergusson, E; Filliter, C; Montastruc, F; Rej, S; Renoux, C; Yu, OHY | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Denis, P; Hoertel, N; Lemogne, C; Lesuffleur, T; Limosin, F; Ouazana-Vedrines, C; Rachas, A; Tuppin, P | 1 |
66 review(s) available for paroxetine and citalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Biochemical pharmacology of the serotonin system.
Topics: Alanine; Brain; Citalopram; Clomipramine; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Neurons; Oximes; p-Chloroamphetamine; Paroxetine; Piperidines; Propylamines; Receptors, Serotonin; Reserpine; Serotonin; Serotonin Antagonists; Synapses; Tetrabenazine; Zimeldine | 1986 |
Therapeutic effects of serotonin uptake inhibitors in depression.
Topics: 5-Hydroxytryptophan; Alanine; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Imipramine; Oximes; Paroxetine; Piperidines; Propylamines; Serotonin; Serotonin Antagonists; Trazodone; Zimeldine | 1986 |
Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Topics: 1-Naphthylamine; Animals; Citalopram; Cytochrome P-450 Enzyme System; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Stereoisomerism | 1995 |
The pharmacogenetics of the selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents; Citalopram; Cytochrome P-450 Enzyme System; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Pharmacogenetics; Selective Serotonin Reuptake Inhibitors | 1993 |
The role of SSRIs in panic disorder.
Topics: 1-Naphthylamine; Citalopram; Clinical Trials as Topic; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients.
Topics: 1-Naphthylamine; Chromatography; Citalopram; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Medication treatments for panic disorder and social phobia.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Benzodiazepines; Citalopram; Clinical Trials as Topic; Clomipramine; Clonazepam; Dose-Response Relationship, Drug; Female; Humans; Male; Moclobemide; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Piperidines; Recurrence; Selective Serotonin Reuptake Inhibitors; Social Behavior Disorders | 1998 |
The side effect burden associated with drug treatment of panic disorder.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Citalopram; Clonazepam; Humans; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1998 |
SSRI safety in overdose.
Topics: Adult; Child; Citalopram; Drug Overdose; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Poison Control Centers; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 1998 |
Mirtazapine versus selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Pharmacokinetics of selective serotonin reuptake inhibitors.
Topics: Citalopram; Clinical Trials as Topic; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2000 |
Serotonin agents in the treatment of acquired brain injury.
Topics: Brain Injuries; Citalopram; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Injury Severity Score; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2002 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior Therapy; Child; Citalopram; Clomipramine; Depression; Diagnosis, Differential; Eczema; Family Practice; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychotherapy; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline; Surveys and Questionnaires; Time Factors; Trichotillomania | 2003 |
Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
Topics: Autistic Disorder; Citalopram; Clinical Trials as Topic; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Fluoxetine; Fluvoxamine; Humans; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2005 |
Discontinuation symptoms in depression and anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Withholding Treatment | 2007 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Trazodone; Venlafaxine Hydrochloride | 2006 |
Pharmacotherapy of child and adolescent depression.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Sertraline; Social Behavior | 2006 |
[Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Case-Control Studies; Child, Preschool; Citalopram; Confidence Intervals; Depressive Disorder; Family Practice; Female; Fluoxetine; Fluvoxamine; History, Medieval; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Placebos; Psychotherapy; Randomized Controlled Trials as Topic; Risk; Safety; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Suicide; Suicide, Attempted | 2006 |
Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
Topics: Adrenergic alpha-Agonists; Algorithms; Amines; Citalopram; Clonidine; Complementary Therapies; Cyclohexanecarboxylic Acids; Estrogen Replacement Therapy; Evidence-Based Medicine; Female; Fluoxetine; Gabapentin; gamma-Aminobutyric Acid; Hot Flashes; Humans; Life Style; Menopause; Middle Aged; Nurse Practitioners; Paroxetine; Patient Education as Topic; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Safety Management; Selective Serotonin Reuptake Inhibitors | 2007 |
Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Fluoxetine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide | 2007 |
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2008 |
Consequences of changes in BDNF levels on serotonin neurotransmission, 5-HT transporter expression and function: studies in adult mice hippocampus.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Hippocampus; Mice; Microdialysis; Paroxetine; RNA, Messenger; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2008 |
Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders.
Topics: Antiretroviral Therapy, Highly Active; Brain; Citalopram; Cognition Disorders; HIV Infections; Humans; Lithium Carbonate; Mental Disorders; Paroxetine; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Valproic Acid | 2008 |
Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.
Topics: Adult; Citalopram; Female; Fluoxetine; Fluvoxamine; Humans; Odds Ratio; Paroxetine; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2008 |
[Severe forms of depression: the efficacy of escitalopram].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Follow-Up Studies; Humans; Paroxetine; Personality Inventory; Psychometrics; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Generalised anxiety disorder.
Topics: Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Double-Blind Method; Humans; Paroxetine; Remission Induction; Sertraline | 2007 |
Antidepressant medication use during breastfeeding.
Topics: Antidepressive Agents, Second-Generation; Breast Feeding; Citalopram; Depression, Postpartum; Female; Fluoxetine; Humans; Infant; Lactation; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors; Sertraline | 2009 |
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Young Adult | 2010 |
Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
Topics: Citalopram; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Placebo Effect; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.
Topics: Abnormalities, Drug-Induced; Cardiovascular Abnormalities; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Humans; Maternal-Fetal Exchange; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Sertraline; Teratogens | 2010 |
[Selective serotonin reuptake inhibitors and mammary pathologies].
Topics: Antidepressive Agents; Breast Neoplasms; Citalopram; Clinical Trials as Topic; Female; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Topics: Benzofurans; Citalopram; Depressive Disorder; Drug Monitoring; Fluoxetine; Fluvoxamine; Humans; Indoles; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Vilazodone Hydrochloride | 2012 |
Citalopram versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depression; Humans; Morpholines; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Duloxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Desvenlafaxine Succinate; Dibenzothiazepines; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Newer generation antidepressants for depressive disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Fluoxetine; Humans; Induction Chemotherapy; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Stroke; Stroke Rehabilitation | 2012 |
Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence; Thiophenes; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Depression; Double-Blind Method; Hepatitis C, Chronic; Humans; Interferon-alpha; Paroxetine; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2013 |
A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
Topics: Allosteric Site; Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder, Major; Drug Interactions; Evidence-Based Medicine; Humans; Models, Biological; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2014 |
Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome.
Topics: Citalopram; Fluoxetine; Humans; Irritable Bowel Syndrome; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2014 |
The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
Topics: Adult; Aged; Citalopram; Desvenlafaxine Succinate; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Middle Aged; Paroxetine; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Vasomotor System; Venlafaxine Hydrochloride | 2015 |
A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; China; Citalopram; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2014 |
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Norepinephrine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Tension-Type Headache; Venlafaxine Hydrochloride | 2015 |
Selective serotonin reuptake inhibitors for fibromyalgia syndrome.
Topics: Amitriptyline; Citalopram; Fibromyalgia; Fluoxetine; Humans; Melatonin; Musculoskeletal Pain; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Syndrome | 2015 |
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2016 |
Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Humans; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Clinical Trials as Topic; Data Interpretation, Statistical; Depression; Humans; Paroxetine; Reproducibility of Results; Sensitivity and Specificity; Sertraline; Venlafaxine Hydrochloride | 2017 |
Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
Topics: Adult; Akathisia, Drug-Induced; Anxiety; Citalopram; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Psychomotor Agitation; Selective Serotonin Reuptake Inhibitors; Sertraline | 2017 |
What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence.
Topics: Adult; Anxiety; Citalopram; Depression; Female; Humans; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Serotonin | 2017 |
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Antidepressant pharmacogenetics in children and young adults: A systematic review.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mental Disorders; Nortriptyline; Paroxetine; Pharmacogenetics; Serotonin Plasma Membrane Transport Proteins; Sertraline; Tryptophan Hydroxylase; Venlafaxine Hydrochloride; Young Adult | 2019 |
Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Cardiovascular Diseases; China; Citalopram; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2019 |
Antidepressants for anxiety disorders in late-life: A systematic review.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Citalopram; Duloxetine Hydrochloride; Humans; Late Onset Disorders; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2019 |
Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: an individual participant data meta-analysis of 1219 patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Randomized Controlled Trials as Topic; Young Adult | 2021 |
Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain.
Topics: Algorithms; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder; Desvenlafaxine Succinate; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Psychometrics; Sertraline; Treatment Outcome | 2020 |
A Systematic Review on the Genotoxic Effects of Selective Serotonin Reuptake Inhibitors.
Topics: Citalopram; Diabetes Mellitus, Type 2; DNA Damage; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2021 |
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mirtazapine; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicidal Ideation; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2021 |
Recent sample pretreatment methods for determination of selective serotonin reuptake inhibitors (SSRIs) in biological samples.
Topics: Citalopram; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2021 |
Are all antidepressants the same? The consumer has a point.
Topics: Antidepressive Agents; Bupropion; Citalopram; Fluoxetine; Humans; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2023 |
[Sexual side effects from treatment with SSRI].
Topics: Citalopram; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunction, Physiological | 2022 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
47 trial(s) available for paroxetine and citalopram
| Article | Year |
|---|---|
Mortality in major affective disorder: relationship to subtype of depression. The Danish University Antidepressant Group.
Topics: Adult; Aged; Citalopram; Clomipramine; Denmark; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Placebos; Prospective Studies; Psychiatric Status Rating Scales; Risk Factors; Sex Factors; Suicide | 1993 |
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Chromatography, High Pressure Liquid; Citalopram; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sparteine | 1996 |
Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Female; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Single-Blind Method | 1997 |
A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
Topics: Adult; Aged; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Placebo Effect; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Outcome | 1998 |
Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Buspirone; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological | 1999 |
Paroxetine versus citalopram treatment of pathological crying after brain injury.
Topics: Adult; Aged; Brain Damage, Chronic; Brain Injuries; Citalopram; Crying; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Laughter; Male; Middle Aged; Neuropsychological Tests; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.
Topics: Administration, Oral; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Citalopram; Delusions; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Inpatients; Male; Middle Aged; Olanzapine; Paroxetine; Patient Discharge; Pirenzepine; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 2001 |
A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Fear; Female; Humans; Male; Panic Disorder; Paroxetine; Psychiatric Status Rating Scales; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome | 2001 |
Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.
Topics: Adult; Binding Sites; Biological Transport; Brain; Caudate Nucleus; Chromatography, High Pressure Liquid; Citalopram; Corpus Striatum; Depressive Disorder, Major; Female; Gyrus Cinguli; Humans; Male; Middle Aged; Paroxetine; Prefrontal Cortex; Putamen; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Thalamus; Tomography, Emission-Computed | 2001 |
SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Chi-Square Distribution; Citalopram; Double-Blind Method; Ejaculation; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; United States | 2002 |
Citalopram treatment of paroxetine-intolerant depressed patients.
Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Drug Tolerance; Female; Humans; Male; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2002 |
Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram.
Topics: Adult; Citalopram; Cross-Over Studies; Double-Blind Method; Drug Evaluation; Electroencephalography; Female; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep, REM; Surveys and Questionnaires | 2004 |
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Topics: Adult; Ambulatory Care; Citalopram; Clomipramine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Male; Obesity; Obsessive-Compulsive Disorder; Paroxetine; Patient Compliance; Prospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2004 |
Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder.
Topics: Adult; Affect; Agoraphobia; Citalopram; Cognition; Cross-Sectional Studies; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychomotor Performance; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
Topics: Buspirone; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Norway; Paroxetine; Placebos; Psychiatric Status Rating Scales; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Sweden | 2005 |
Dopaminergic mechanism of antidepressant action in depressed patients.
Topics: Adult; Affect; Case-Control Studies; Citalopram; Depressive Disorder, Major; Dopamine Antagonists; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Activity; Paroxetine; Receptors, Dopamine D2; Receptors, Dopamine D3; Selective Serotonin Reuptake Inhibitors; Sulpiride; Treatment Outcome | 2005 |
Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions.
Topics: Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Dose-Response Relationship, Drug; Factor Analysis, Statistical; Humans; Paroxetine; Retrospective Studies; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2006 |
The effect of pharmacotherapy on personality disorders in panic disorder: a one year naturalistic study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Comorbidity; Female; Follow-Up Studies; Humans; Male; Middle Aged; Panic Disorder; Paroxetine; Personality Assessment; Personality Disorders; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Antidepressant treatment outcomes of psychogenic movement disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Combined Modality Therapy; Comorbidity; Conversion Disorder; Cyclohexanols; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Hypochondriasis; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
T3 augmentation of SSRI resistant depression.
Topics: Adult; Aged; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Resistance; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Triiodothyronine | 2006 |
A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
Topics: Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sexual Dysfunction, Physiological; Suicide, Attempted; Tablets; Time Factors; Treatment Outcome; Withholding Treatment | 2006 |
A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Safety | 2006 |
Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study.
Topics: Adult; Aged; Anxiety Disorders; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2006 |
Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Patient Dropouts; Placebos; Reference Standards; Remission Induction; Treatment Outcome | 2007 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
Combined brief dynamic therapy and pharmacotherapy in the treatment of major depressive disorder: a pilot study.
Topics: Adolescent; Adult; Aged; Citalopram; Combined Modality Therapy; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Paroxetine; Pilot Projects; Psychotherapy, Brief; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2007 |
Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache.
Topics: Adult; Character; Chronic Disease; Citalopram; Female; Fluoxetine; Harm Reduction; Humans; Internal-External Control; Male; Paroxetine; Personal Autonomy; Personality Inventory; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Temperament; Tension-Type Headache | 2007 |
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Treatment Outcome | 2007 |
Effect of pharmacological treatment on temperament and character in panic disorder.
Topics: Adult; Anxiety; Character; Citalopram; Female; Follow-Up Studies; GABA Modulators; Humans; Lorazepam; Male; Panic Disorder; Paroxetine; Personality Disorders; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Temperament | 2008 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Personality Assessment; Personality Inventory; Psychometrics; Treatment Outcome | 2008 |
Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants.
Topics: Adult; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; Chi-Square Distribution; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Matched-Pair Analysis; Neuropsychological Tests; Paroxetine; Reference Values; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Patient Compliance; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; Thiophenes; Treatment Outcome | 2009 |
Superiority of escitalopram to paroxetine in the treatment of depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paroxetine; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Suicide; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Time Factors | 2010 |
[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Psychometrics | 2010 |
Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Drug Substitution; Female; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Sertraline; Time Factors; Treatment Outcome | 2011 |
Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Cyclohexanols; Double-Blind Method; Drug Therapy, Combination; Europe; Female; gamma-Aminobutyric Acid; Humans; Kaplan-Meier Estimate; Least-Squares Analysis; Linear Models; Male; Middle Aged; Odds Ratio; Paroxetine; Placebos; Pregabalin; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2012 |
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Body Mass Index; Child; Citalopram; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients.
Topics: Adult; Aripiprazole; Asian People; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Electrocardiography; Electroencephalography; Female; Genotype; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Piperazines; Quinolones | 2014 |
Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.
Topics: Adult; Antidepressive Agents; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Female; Fluoxetine; Genotype; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Venlafaxine Hydrochloride | 2016 |
SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL.
Topics: Adult; Agoraphobia; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2016 |
[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Topics: Alcoholism; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2021 |
234 other study(ies) available for paroxetine and citalopram
| Article | Year |
|---|---|
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
Topics: Animals; Antidepressive Agents; Biological Assay; Biological Transport; Dose-Response Relationship, Drug; Isoquinolines; Mice; Pyrroles; Rats; Serotonin; Structure-Activity Relationship | 1990 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1.
Topics: Animals; Binding, Competitive; Carrier Proteins; Cell Membrane; Cerebral Cortex; Citalopram; Drug Design; Indicators and Reagents; Kinetics; Membrane Glycoproteins; Membrane Transport Proteins; Models, Structural; Molecular Conformation; Nerve Tissue Proteins; Quipazine; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2000 |
Inhibition of P-glycoprotein by newer antidepressants.
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.
Topics: Animals; Carbon Radioisotopes; Cell Line; Humans; Indoles; Isoquinolines; Isotope Labeling; Ligands; Positron-Emission Tomography; Propylamines; Rats; Rats, Inbred Strains; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2008 |
3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.
Topics: Carbon; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Drug Design; Fluorine Radioisotopes; Humans; In Vitro Techniques; Indoles; Inhibitory Concentration 50; Kinetics; Membrane Transport Proteins; Models, Chemical; Nitriles; Quinolines; Radiopharmaceuticals; Serotonin Plasma Membrane Transport Proteins | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.
Topics: Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Ligands; Models, Molecular; Molecular Structure; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2021 |
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Topics: 1-Naphthylamine; Antidepressive Agents, Tricyclic; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sparteine | 1992 |
[3H]citalopram binding to brain and platelet membranes of human and rat.
Topics: Animals; Binding Sites; Blood Platelets; Brain; Carrier Proteins; Cell Membrane; Citalopram; Humans; Imipramine; Kinetics; Neurons; Paroxetine; Piperidines; Rats; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Temperature; Thermodynamics | 1991 |
Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets.
Topics: Animals; Blood Platelets; Brain; Carrier Proteins; Cell Membrane; Citalopram; Half-Life; Humans; Imipramine; In Vitro Techniques; Membrane Proteins; Paroxetine; Piperidines; Rats; Serotonin Plasma Membrane Transport Proteins | 1991 |
No crossover reactions to citalopram or paroxetine among patients hypersensitive to zimeldine.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Combined Modality Therapy; Depressive Disorder; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Liver Function Tests; Male; Paroxetine; Piperidines; Serotonin Antagonists; Zimeldine | 1991 |
Regional distribution of the serotonin transport complex in human brain, identified with 3H-paroxetine, 3H-citalopram and 3H-imipramine.
Topics: Adolescent; Adult; Aged; Binding, Competitive; Biological Transport; Brain; Citalopram; Female; Humans; Imipramine; Kinetics; Male; Membranes; Middle Aged; Organ Specificity; Paroxetine; Piperidines; Receptors, Serotonin; Serotonin; Serotonin Antagonists | 1990 |
Serotonergic and catecholaminergic reuptake inhibitors have opposite effects on the ultrasonic isolation calls of rat pups.
Topics: Animals; Body Temperature; Catecholamines; Citalopram; Clomipramine; Desipramine; Flumazenil; Mazindol; Motor Activity; Naltrexone; Nortriptyline; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Serotonin Antagonists; Stress, Psychological; Ultrasonics; Vocalization, Animal | 1990 |
Inhibitory and regulatory binding sites on the rat brain serotonin transporter: molecular weight of the [3H]paroxetine and [3H]citalopram binding proteins.
Topics: Animals; Biological Transport, Active; Brain; Carrier Proteins; Citalopram; Half-Life; In Vitro Techniques; Kinetics; Models, Biological; Molecular Weight; Paroxetine; Piperidines; Rats; Receptors, Serotonin | 1990 |
Interaction between serotonin uptake inhibitors and alpha-2 adrenergic heteroreceptors in the rat hypothalamus.
Topics: Animals; Brimonidine Tartrate; Citalopram; Fenclonine; Hypothalamus; In Vitro Techniques; Male; Norepinephrine; Paroxetine; Piperidines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Serotonin; Serotonin; Serotonin Antagonists | 1990 |
High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue.
Topics: Aged; Aged, 80 and over; Binding, Competitive; Brain; Citalopram; Female; Humans; Kinetics; Male; Middle Aged; Paroxetine; Piperidines; Receptors, Serotonin | 1989 |
Drug inhibition indicates a single-site model of the 5-HT uptake site/antidepressant binding site in rat and human brain.
Topics: Aged; Animals; Antidepressive Agents; Binding Sites; Brain; Citalopram; Clomipramine; Humans; In Vitro Techniques; Male; Middle Aged; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Serotonin | 1989 |
A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter.
Topics: Animals; Antidepressive Agents, Tricyclic; Binding Sites; Binding, Competitive; Biological Transport; Cerebral Cortex; Citalopram; Dose-Response Relationship, Drug; Ethylmaleimide; Fluoxetine; Imipramine; Male; Neurons; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Sodium | 1989 |
Interaction between tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors and the presynaptic 5-hydroxytryptamine inhibitory autoreceptors in the rat hypothalamus.
Topics: 5-Methoxytryptamine; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Citalopram; Electric Stimulation; Fenclonine; Hypothalamus; Imipramine; Lysergic Acid Diethylamide; Male; Methiothepin; Neurotransmitter Agents; Pargyline; Paroxetine; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin | 1985 |
Effects of antidepressant drug combinations on cortical 5-HT2 receptors and wet-dog shakes in rats.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Carbidopa; Cerebral Cortex; Citalopram; Drug Interactions; Fenfluramine; Male; Methoxydimethyltryptamines; Paroxetine; Phenelzine; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Receptors, Serotonin; Reflex; Serotonin; Time Factors | 1985 |
Antidepressive drugs can change the affinity of [3H]imipramine and [3H]paroxetine binding to platelet and neuronal membranes.
Topics: Animals; Antidepressive Agents; Binding Sites; Binding, Competitive; Blood Platelets; Brain; Cell Membrane; Citalopram; Imipramine; In Vitro Techniques; Kinetics; Paroxetine; Piperidines; Propylamines; Rats; Serotonin; Serotonin Antagonists; Synaptic Membranes | 1985 |
High- and low-affinity binding of [3H]imipramine in rat hypothalamus.
Topics: Amitriptyline; Animals; Citalopram; Clomipramine; Cyclopropanes; Hypothalamus; Imipramine; Kinetics; Male; Milnacipran; Paroxetine; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Serotonin; Sodium | 1986 |
Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat.
Topics: Animals; Cerebral Cortex; Citalopram; Clomipramine; Clorgyline; Kinetics; Male; Membranes; Monoamine Oxidase Inhibitors; Paroxetine; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Selegiline; Serotonin | 1987 |
Characterization of [3H]paroxetine binding in rat brain.
Topics: Animals; Binding, Competitive; Brain; Cell Membrane; Cerebral Cortex; Citalopram; Fluoxetine; Imipramine; Male; Paroxetine; Peptide Hydrolases; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Serotonin; Serotonin Antagonists; Tritium | 1988 |
Dissociation kinetics of [3H]paroxetine binding to rat brain consistent with a single-site model of the antidepressant binding/5-hydroxytryptamine uptake site.
Topics: Animals; Brain; Cell Membrane; Citalopram; Clomipramine; Imipramine; Kinetics; Male; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Serotonin; Serotonin Antagonists; Zimeldine | 1988 |
Differences in brain 5-HT transporter dissociation rates among animal species.
Topics: Adrenergic Uptake Inhibitors; Animals; Biological Transport, Active; Brain Chemistry; Citalopram; Humans; Imipramine; Mice; Paroxetine; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Swine | 1995 |
Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors.
Topics: 1-Naphthylamine; 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Aggression; Analysis of Variance; Animals; Behavior, Animal; Brain; Citalopram; Dose-Response Relationship, Drug; Fenclonine; Fluoxetine; Fluvoxamine; Male; Mice; Paroxetine; Penbutolol; Piperidines; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Sertraline; Synaptosomes | 1994 |
Differential effects of 5,7-dihydroxytryptamine-induced serotoninergic degeneration of 5-HT1A receptors and 5-HT uptake sites in the rat brain.
Topics: 5,7-Dihydroxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autoradiography; Brain; Citalopram; Male; Nerve Degeneration; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Reserpine; Serotonin | 1994 |
Different effects of antidepressants on dissociation of 3H-imipramine from solubilized binding sites of rat brain.
Topics: Animals; Antidepressive Agents; Binding Sites; Brain; Carrier Proteins; Citalopram; Dose-Response Relationship, Drug; Imipramine; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Paroxetine; Rats; Rats, Wistar; Serotonin; Serotonin Plasma Membrane Transport Proteins | 1994 |
Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine.
Topics: Adult; Biomarkers; Blood Platelets; Cell Membrane; Citalopram; Depressive Disorder; Desipramine; Female; Humans; Imipramine; In Vitro Techniques; Male; Middle Aged; Paroxetine; Receptors, Serotonin; Sodium | 1993 |
[3H]paroxetine and [3H]citalopram as markers of the human brain 5-HT uptake site: a comparison study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Binding, Competitive; Biomarkers; Brain Chemistry; Citalopram; Female; Humans; In Vitro Techniques; Male; Membranes; Middle Aged; Paroxetine; Rats; Receptors, Serotonin | 1994 |
Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Autoreceptors; Citalopram; Hippocampus; Male; Microdialysis; Paroxetine; Pindolol; Piperazines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stereoisomerism | 1994 |
The serotonin transporter in depressed patients: a qualitative study based on dissociation kinetics.
Topics: Adult; Aged; Blood Platelets; Carrier Proteins; Citalopram; Female; Half-Life; Humans; Imipramine; Ligands; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Protein Binding; Serotonin; Serotonin Plasma Membrane Transport Proteins; Statistics, Nonparametric | 1995 |
The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.
Topics: Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Fluoxetine; Humans; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1995 |
5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI).
Topics: Animals; Citalopram; Hippocampus; Male; Microdialysis; Paroxetine; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin | 1996 |
Mania associated with serotonin selective reuptake inhibitors.
Topics: Bipolar Disorder; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1997 |
Protective effect of citalopram against the attenuation of the alpha 1-potentiation of cAMP formation in Fischer 344 strain rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Body Weight; Brain Chemistry; Citalopram; Cyclic AMP; Depression; Imipramine; Male; Motor Activity; Nerve Tissue Proteins; Paroxetine; Radioligand Assay; Rats; Rats, Inbred F344; Receptors, Adrenergic, alpha-1; Selective Serotonin Reuptake Inhibitors; Stress, Psychological | 1997 |
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Topics: 1-Naphthylamine; Aggression; Animals; Anxiety; Binding, Competitive; Citalopram; Depression; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Rats; Rats, Wistar; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sertraline; Vocalization, Animal | 1997 |
Behavioural effects of selective serotonin reuptake inhibitors following direct micro injection into the left red nucleus of the rat.
Topics: 1-Naphthylamine; Animals; Behavior, Animal; Chlorpromazine; Citalopram; Fluoxetine; Fluvoxamine; Guanidines; Haloperidol; Male; Microinjections; Motor Activity; Paroxetine; Piperidines; Posture; Rats; Rats, Sprague-Dawley; Receptors, sigma; Red Nucleus; Selective Serotonin Reuptake Inhibitors; Sertraline | 1997 |
Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors.
Topics: Animals; Autoradiography; Autoreceptors; Citalopram; Dendrites; Male; Microdialysis; Paroxetine; Piperazines; Prosencephalon; Pyridines; Raphe Nuclei; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Serotonin; Serotonin Antagonists; Tritium | 1997 |
Radiosynthesis and PET imaging of [N-methyl-11C]LY257327 as a tracer for 5-HT transporters.
Topics: Animals; Brain; Carrier Proteins; Chromatography, High Pressure Liquid; Citalopram; Female; Isotope Labeling; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Ovariectomy; Papio; Paroxetine; Piperazines; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Spectrophotometry, Ultraviolet; Tetrahydronaphthalenes; Tomography, Emission-Computed | 1997 |
Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry.
Topics: 1-Naphthylamine; Citalopram; Drug Monitoring; Gas Chromatography-Mass Spectrometry; Humans; Paroxetine; Quality Control; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Anti-Arrhythmia Agents; Child; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Kinetics; Male; Methylation; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Exercise Test; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 1998 |
[Withdrawal symptoms in connection with the use of selective serotonin reuptake inhibitors (SSRI)].
Topics: Adult; Antidepressive Agents; Citalopram; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 1998 |
Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
Topics: Adolescent; Adult; Child; Citalopram; Cytochrome P-450 Enzyme System; Drug Prescriptions; Fluoxetine; Fluvoxamine; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline.
Topics: Animals; Biogenic Monoamines; Cerebral Cortex; Citalopram; Clozapine; Corpus Striatum; Diazepam; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; GABA Agents; Male; Norepinephrine; Nucleus Accumbens; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline | 1999 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |
Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Excitatory Amino Acid Antagonists; Fluoxetine; Male; Motor Activity; Paroxetine; Phencyclidine; Rats; Rats, Sprague-Dawley | 1999 |
Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers.
Topics: Animals; Citalopram; Evoked Potentials; Locus Coeruleus; Male; Neurons; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 1999 |
Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Citalopram; Disease Models, Animal; Eating; Ethanol; Female; Fluoxetine; Fluvoxamine; Food Preferences; Male; Paroxetine; Rats; Rats, Mutant Strains; Selective Serotonin Reuptake Inhibitors | 1999 |
Molecular cloning, expression and characterization of a bovine serotonin transporter.
Topics: Amino Acid Sequence; Animals; Carrier Proteins; Cattle; Citalopram; Cloning, Molecular; Desipramine; Female; Fluoxetine; HeLa Cells; Humans; Imipramine; Kinetics; Membrane Glycoproteins; Membrane Transport Proteins; Molecular Sequence Data; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Organ Specificity; Paroxetine; Phylogeny; Pregnancy; Rats; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Alignment; Sequence Homology, Amino Acid; Serotonin; Serotonin Plasma Membrane Transport Proteins; Transfection | 1999 |
Effects of "Ecstasy" blocked by serotonin reuptake inhibitors.
Topics: Adult; Citalopram; Female; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Trichotillomania | 1999 |
Excretion of paroxetine into breast milk.
Topics: Adult; Breast Feeding; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluoxetine; Fluvoxamine; Humans; Lactation; Milk, Human; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Triglycerides | 1999 |
[Severe withdrawal symptoms with fever upon stopping paroxetine].
Topics: Citalopram; Drug Administration Schedule; Fever; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome | 1999 |
Serotonin transporter production and degradation rates: studies with RTI-76.
Topics: Animals; Carrier Proteins; Cerebral Cortex; Cerebral Ventricles; Citalopram; Cocaine; Half-Life; Injections, Intraventricular; Kinetics; Male; Membrane Glycoproteins; Membrane Transport Proteins; Models, Neurological; Nerve Tissue Proteins; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tropanes | 1999 |
Citalopram: new indication. No advantage.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Clomipramine; Double-Blind Method; Humans; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1999 |
Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fluorescence detection.
Topics: Acetonitriles; Chromatography, High Pressure Liquid; Citalopram; Fluoxetine; Humans; Hydrogen-Ion Concentration; Paroxetine; Quality Control; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 1999 |
Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
Topics: Animals; Autoradiography; Binding Sites; Biological Transport; Brain; Citalopram; Dopamine; Immunohistochemistry; In Situ Hybridization; In Vitro Techniques; Ligands; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Norepinephrine; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Reserpine; Selective Serotonin Reuptake Inhibitors; Serotonin; Tetrabenazine; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2000 |
Lack of desipramine toxicity with citalopram.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cytochrome P-450 CYP2D6; Depressive Disorder; Desipramine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Liver; Middle Aged; Paroxetine | 2000 |
Female sexual dysfunction and antidepressant use.
Topics: Amantadine; Antidepressive Agents; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Meta-Analysis as Topic; Paroxetine; Personality Inventory; Placebos; Sexual Dysfunctions, Psychological; Treatment Outcome | 2001 |
Disinhibition of libido: an adverse effect of SSRI?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Citalopram; Depression; Female; Humans; Libido; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Switzerland | 2001 |
An ideal trial to test differential onset of antidepressant effect.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder; Humans; Paroxetine; Placebos; Prospective Studies; Research Design; Terminology as Topic; Time Factors; Treatment Outcome | 2001 |
Does mirtazapine have a more rapid onset than SSRIs?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cross-Sectional Studies; Data Interpretation, Statistical; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Patient Dropouts; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
[The transfer of selective serotonin reuptake inhibitors to human milk].
Topics: Antidepressive Agents; Breast Feeding; Citalopram; Depression, Postpartum; Female; Fluoxetine; Fluvoxamine; Humans; Infant; Infant, Newborn; Milk, Human; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
Clinical predictors of drug response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Citalopram; Clomipramine; Drug Resistance; Female; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Predictive Value of Tests; Psychological Tests; Random Allocation; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue.
Topics: Animals; Citalopram; Electric Stimulation; Erectile Dysfunction; Male; Neurons; Nitric Oxide; Nitric Oxide Synthase; Paroxetine; Penile Erection; Penis; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2001 |
Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma by temperature-programmed packed capillary liquid chromatography with on-column focusing of large injection volumes.
Topics: Chromatography, Liquid; Citalopram; Fluoxetine; Humans; Paroxetine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2002 |
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines.
Topics: Animals; Binding, Competitive; Carrier Proteins; Cerebral Cortex; Citalopram; Drug Design; Fluoxetine; Inhibitory Concentration 50; Kinetics; Male; Membrane Glycoproteins; Membrane Transport Proteins; Models, Structural; Nerve Tissue Proteins; Paroxetine; Quipazine; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2002 |
5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors.
Topics: Apoptosis; Biopsy; Blotting, Western; Burkitt Lymphoma; Carrier Proteins; Caspases; Cell Survival; Citalopram; DNA Damage; DNA, Neoplasm; Fluoxetine; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tumor Cells, Cultured | 2002 |
Block of volume-regulated anion channels by selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents; Cells, Cultured; Chloride Channels; Citalopram; Dose-Response Relationship, Drug; Endothelium, Vascular; Fluvoxamine; Humans; Hydrogen-Ion Concentration; Hypotonic Solutions; Inhibitory Concentration 50; Membrane Potentials; Paroxetine; Patch-Clamp Techniques; Pulmonary Artery; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Predosing with the unlabeled "inactive" enantiomer as a tool for improvement of the PET signal.
Topics: Animals; Brain Chemistry; Carrier Proteins; Citalopram; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Tomography, Emission-Computed | 2002 |
Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity.
Topics: Animals; Cells, Cultured; Citalopram; Hippocampus; Imipramine; Male; Microdialysis; Nitric Oxide; Nitroarginine; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Thiazepines; Time Factors | 2003 |
Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells.
Topics: Apoptosis; B-Lymphocytes; Burkitt Lymphoma; Calcium Signaling; Carrier Proteins; Citalopram; Fluoxetine; Gene Expression Regulation; Genes, bcl-2; Genes, myc; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Monocytes; Monomeric GTP-Binding Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Nerve Tissue Proteins; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Paroxetine; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Transcription Factors | 2003 |
Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2).
Topics: Acute Disease; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biopsy; Cholestasis; Citalopram; Dothiepin; Female; Humans; Immunohistochemistry; Liver; Male; Middle Aged; Mitochondrial Proteins; Paroxetine; Pregnancy; Pregnancy Complications; Ribosomal Proteins; Saccharomyces cerevisiae Proteins | 2003 |
SSRIs and ejaculation.
Topics: Adult; Citalopram; Dose-Response Relationship, Drug; Ejaculation; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2003 |
Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center.
Topics: Citalopram; Clinical Pharmacy Information Systems; Cost Control; Cost Savings; Drug Administration Schedule; Drug Costs; Drug Utilization; Fluoxetine; Fluvoxamine; Hospital Costs; Hospitals, Veterans; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2003 |
Olanzapine and serotonin toxicity.
Topics: Antipsychotic Agents; Benzodiazepines; Citalopram; Drug Therapy, Combination; Humans; Olanzapine; Paroxetine; Pirenzepine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Substance Withdrawal Syndrome | 2003 |
Placental passage of antidepressant medications.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fetal Blood; Fluoxetine; Humans; Maternal-Fetal Exchange; Paroxetine; Placenta; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Sertraline | 2003 |
Antidepressant-like effects in various mice strains in the tail suspension test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Bupropion; Citalopram; Depression; Desipramine; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Hindlimb Suspension; Imipramine; Male; Mice; Mice, Inbred Strains; Paroxetine; Selective Serotonin Reuptake Inhibitors; Species Specificity | 2003 |
Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Dose-Response Relationship, Drug; Frontal Lobe; Male; Mice; Microdialysis; Norepinephrine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors; Venlafaxine Hydrochloride | 2003 |
Selective serotonin reuptake inhibitors in pilot fatalities of civil aviation accidents, 1990-2001.
Topics: Accidents, Aviation; Aerospace Medicine; Certification; Citalopram; Databases as Topic; Environmental Monitoring; Fluoxetine; Humans; Paroxetine; Postmortem Changes; Selective Serotonin Reuptake Inhibitors; Sertraline; Survival Rate; United States | 2003 |
Mechanisms for the inhibition of genital vascular responses by antidepressants in a female rabbit model.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Blood Vessels; Citalopram; Cyclohexanols; Drug Interactions; Duloxetine Hydrochloride; Female; Nitric Oxide; Norepinephrine; Paroxetine; Phentolamine; Rabbits; Regional Blood Flow; Selective Serotonin Reuptake Inhibitors; Serotonin; Thiophenes; Vagina; Vasodilation; Venlafaxine Hydrochloride | 2004 |
Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Doxepin; Drug Overdose; Drug Prescriptions; Emergency Service, Hospital; Female; Fluoxetine; Humans; Imipramine; Information Services; Male; Mianserin; Mirtazapine; Paroxetine; Patient Admission; Patient Readmission; Poison Control Centers; Retrospective Studies; Risk Assessment; Scotland; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Trazodone; Venlafaxine Hydrochloride | 2004 |
A comparative solid-phase extraction study for the simultaneous determination of fluvoxamine, mianserin, doxepin, citalopram, paroxetine, and etoperidone in whole blood by capillary gas-liquid chromatography with nitrogen-phosphorus detection.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chromatography, Gas; Chromatography, Liquid; Citalopram; Doxepin; Female; Fluvoxamine; Humans; Mianserin; Nitrogen; Paroxetine; Phosphorus; Reproducibility of Results; Trazodone | 2004 |
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
Topics: Adult; Benzylamines; Carbon Radioisotopes; Carrier Proteins; Citalopram; Corpus Striatum; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline; Tomography, Emission-Computed; Venlafaxine Hydrochloride | 2004 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Droxidopa; Fluoxetine; Gene Deletion; Mice; Morpholines; Norepinephrine; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Tail | 2004 |
Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine.
Topics: Citalopram; Depressive Disorder; Drug Administration Schedule; Fatigue; Fluoxetine; Humans; Paroxetine; Quality of Life; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Neonatal complications after intrauterine exposure to SSRI antidepressants.
Topics: Antidepressive Agents; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; France; Humans; Infant, Newborn; Neonatal Abstinence Syndrome; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Risk; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work | 2004 |
Acute and chronic toxicity of five selective serotonin reuptake inhibitors in Ceriodaphnia dubia.
Topics: Animals; Citalopram; Cladocera; Ecosystem; Female; Fluoxetine; Fluvoxamine; Lethal Dose 50; Male; No-Observed-Adverse-Effect Level; Paroxetine; Reproduction; Selective Serotonin Reuptake Inhibitors; Sertraline; Toxicity Tests, Acute; Toxicity Tests, Chronic; Water Pollutants, Chemical | 2004 |
Selective serotonin reuptake inhibitors induce spontaneous interneuronal activity in the leech nervous system.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Animals; Citalopram; Drug Interactions; Electric Stimulation; Fluoxetine; Ganglia, Invertebrate; Imipramine; In Vitro Techniques; Interneurons; Leeches; Membrane Potentials; Neural Networks, Computer; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Synapses | 2005 |
Binding of S-citalopram and paroxetine discriminates between species.
Topics: Animals; Benzylamines; Binding, Competitive; Brain; Cells, Cultured; Chickens; Citalopram; Evolution, Molecular; Humans; Isoquinolines; Ligands; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Paroxetine; Radioligand Assay; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Sertraline; Species Specificity; Tritium | 2005 |
Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
Topics: Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Citalopram; Cyclohexanols; Depression; Female; Fluoxetine; Humans; Male; Paroxetine; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Venlafaxine Hydrochloride | 2005 |
Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Anxiety Disorders; Citalopram; Cohort Studies; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Patient Compliance; Patient Dropouts; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic | 2005 |
Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.
Topics: Adult; Citalopram; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Netherlands; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Surveys and Questionnaires; Time Factors | 2005 |
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study.
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal Relations; Male; Panic Disorder; Paroxetine; Pilot Projects; Problem Solving; Psychotherapy; Quality of Life; Selective Serotonin Reuptake Inhibitors | 2005 |
alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Citalopram; Clonidine; Cyclohexanols; Cyclopropanes; Dose-Response Relationship, Drug; Drug Antagonism; Guanabenz; Male; Mice; Milnacipran; Motor Activity; Paroxetine; Punishment; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Venlafaxine Hydrochloride | 2005 |
[The serotonin syndrome].
Topics: Aged; Antipsychotic Agents; Citalopram; Depressive Disorder; Dibenzothiepins; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Middle Aged; Neurologic Examination; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Serotonin Syndrome | 2005 |
Selective serotonin re-uptake inhibition attenuates evoked glutamate release in the dorsal horn of the anaesthetised rat in vivo.
Topics: Anesthesia; Animals; Aspartic Acid; Citalopram; Glutamic Acid; Male; Microdialysis; Paroxetine; Piperazines; Posterior Horn Cells; Pyridines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2006 |
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin.
Topics: Antidepressive Agents, Second-Generation; Biological Availability; Catechol O-Methyltransferase; Citalopram; Depressive Disorder, Major; Dopamine; Ethnicity; Female; Fluvoxamine; Follow-Up Studies; Frontal Lobe; Genetic Carrier Screening; Genotype; Humans; Male; Methionine; Paroxetine; Personality Inventory; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Valine | 2006 |
Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Topics: Action Potentials; Allosteric Regulation; Animals; Antidepressive Agents, Second-Generation; Brain; Chlorocebus aethiops; Citalopram; COS Cells; Drug Interactions; Fluoxetine; Hippocampus; Male; Microdialysis; Paroxetine; Protein Binding; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Transfection | 2007 |
Predictors of symptom resolution in panic disorder after one year of pharmacological treatment: a naturalistic study.
Topics: Adult; Agoraphobia; Anxiety Disorders; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Male; Panic Disorder; Paroxetine; Prospective Studies; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2006 |
Selective serotonin reuptake inhibitors in sewage influents and effluents from Tromsø, Norway.
Topics: Calibration; Chemical Fractionation; Chromatography, High Pressure Liquid; Citalopram; Fluoxetine; Fluvoxamine; Norway; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline; Sewage; Water Pollutants, Chemical | 2006 |
Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.
Topics: Adrenergic alpha-Antagonists; Alprazolam; Animals; Anxiety; Citalopram; Dose-Response Relationship, Drug; Electric Stimulation; Fluoxetine; Hypnotics and Sedatives; Male; Motor Activity; Panic Disorder; Paroxetine; Periaqueductal Gray; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Stereotaxic Techniques; Yohimbine | 2006 |
Comparison of first refill rates among users of sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Anxiety Disorders; Citalopram; Cohort Studies; Cost Sharing; Databases, Factual; Depression; Drug Prescriptions; Female; Humans; Logistic Models; Male; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2006 |
Effect of antidepressant drugs on 6-OHDA-treated mice in the FST.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biogenic Monoamines; Cerebral Cortex; Citalopram; Depression; Desipramine; Dopamine Uptake Inhibitors; Hippocampus; Hypothalamus; Imipramine; Injections, Intraventricular; Male; Mice; Neostriatum; Oxidopamine; Paroxetine; Swimming | 2007 |
Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Desipramine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Escape Reaction; Male; Mice; Neurokinin-1 Receptor Antagonists; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Swimming; Tetrazoles | 2006 |
Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Citalopram; Female; Follow-Up Studies; Humans; Male; Panic Disorder; Paroxetine; Psychiatric Status Rating Scales; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2006 |
Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom.
Topics: Anxiety Disorders; Citalopram; Cost-Benefit Analysis; Decision Support Techniques; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; United Kingdom | 2006 |
Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
Topics: Adolescent; Adult; Aged; Catchment Area, Health; Citalopram; Cost-Benefit Analysis; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Health Expenditures; Humans; Male; Middle Aged; Paroxetine; Primary Health Care; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Spain | 2006 |
Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.
Topics: Action Potentials; Analysis of Variance; Animals; Citalopram; Dopamine; Drug Administration Schedule; Fluoxetine; Male; Mesencephalon; Neurons; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2007 |
Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites.
Topics: Allosteric Regulation; Animals; Antidepressive Agents; Binding Sites; Chlorocebus aethiops; Citalopram; COS Cells; Humans; Mutagenesis, Site-Directed; Paroxetine; Radioligand Assay; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism | 2007 |
Simple options for improving signal detection in antidepressant clinical trials.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Databases, Factual; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Fluoxetine; Likelihood Functions; Models, Statistical; Paroxetine; Personality Inventory; Placebo Effect; Psychometrics; Reproducibility of Results; Research Design; Signal Detection, Psychological; Thiophenes; Treatment Outcome | 2007 |
Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autoradiography; Brain Chemistry; Brain-Derived Neurotrophic Factor; Citalopram; Dose-Response Relationship, Drug; Electrophysiology; Hippocampus; Male; Mice; Mice, Knockout; Microdialysis; Paroxetine; Phenotype; Raphe Nuclei; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Serotonin Receptor Agonists; Synaptic Transmission | 2008 |
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Child; Citalopram; Drug Utilization Review; Female; Fluoxetine; Humans; Hyperprolactinemia; Italy; Male; Medical Records; Mental Disorders; Olanzapine; Paroxetine; Practice Patterns, Physicians'; Retrospective Studies; Risperidone; Sertraline; Treatment Outcome | 2008 |
Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST).
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Clomipramine; Depressive Disorder; Dose-Response Relationship, Drug; Male; Mice; Mice, Knockout; Motor Activity; Paroxetine; Receptors, Dopamine D3; Selective Serotonin Reuptake Inhibitors; Sertraline; Species Specificity; Swimming | 2008 |
Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Topics: Aged; Aged, 80 and over; Algorithms; Bayes Theorem; Citalopram; Cost-Benefit Analysis; Depression; Drugs, Generic; Female; Fluoxetine; Humans; Male; Medicare; Models, Statistical; Paroxetine; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; United States | 2007 |
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Topics: Adult; Citalopram; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Demography; Drug Resistance; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Canada; Chronic Disease; Citalopram; Confidence Intervals; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Monte Carlo Method; Paroxetine; Primary Health Care; Sensitivity and Specificity; Severity of Illness Index | 2008 |
Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice.
Topics: Animals; Citalopram; Male; Mice; Models, Biological; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline | 2008 |
Involvement of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors in the mechanism of antidepressant action.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Cells, Cultured; Citalopram; Imipramine; Neurons; Paroxetine; Pituitary Adenylate Cyclase-Activating Polypeptide; Rats; Rats, Sprague-Dawley; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; Selective Serotonin Reuptake Inhibitors; Signal Transduction | 2008 |
Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Animal; Binding, Competitive; Cell Proliferation; Citalopram; Dentate Gyrus; Desipramine; Hippocampus; Insulin-Like Growth Factor I; Male; Nerve Growth Factors; Paroxetine; Rats; Rats, Sprague-Dawley; Receptor, IGF Type 1; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Swimming; Synaptic Transmission; Tryptophan Hydroxylase | 2008 |
[Sleep spindles in post traumatic stress disorder: significant importance of selective serotonin reuptake inhibitors].
Topics: Citalopram; Electromyography; Electrooculography; Humans; Paroxetine; Reference Values; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep; Sleep Initiation and Maintenance Disorders; Sleep Stages; Sleep, REM; Stress Disorders, Post-Traumatic; Wakefulness | 2008 |
Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Depression; Disease Models, Animal; Drug Synergism; Hippocampus; In Situ Hybridization; Male; Mice; Microdialysis; Microinjections; Motor Activity; Paroxetine; Receptor, trkB; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors | 2009 |
Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes.
Topics: Adult; Birth Weight; Case-Control Studies; Citalopram; Female; Fetal Blood; Fetal Development; Fetal Growth Retardation; Fetus; Fluoxetine; Hormones; Humans; Hypothalamo-Hypophyseal System; Infant, Newborn; Insulin-Like Growth Factor I; Male; Paroxetine; Pituitary-Adrenal System; Placenta; Pregnancy; Selective Serotonin Reuptake Inhibitors | 2009 |
Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief.
Topics: Action Potentials; Animals; Antidepressive Agents; Cell Line, Tumor; Citalopram; Disease Models, Animal; Fluvoxamine; Humans; Injections, Spinal; Male; Pain; Pain Measurement; Paroxetine; Purinergic P2 Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P2X4; Serotonin Antagonists; Spinal Cord | 2009 |
Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Databases as Topic; Depression; Drug Costs; Drug Prescriptions; Drugs, Generic; Female; Fluoxetine; Humans; Insurance, Pharmaceutical Services; Likelihood Functions; Logistic Models; Male; Medication Adherence; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Time Factors; United States | 2009 |
The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Brain; Citalopram; Depression; Disease Models, Animal; Fenclonine; Fenfluramine; Fluorobenzenes; Freezing Reaction, Cataleptic; Male; Paroxetine; Piperidines; Protein Binding; Rats; Rats, Inbred Strains; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT4; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Swimming; Time Factors; Tritium | 2009 |
Fast separation of selective serotonin reuptake inhibitors antidepressants in plasma sample by nonaqueous capillary electrophoresis.
Topics: Antidepressive Agents; Citalopram; Drug Monitoring; Electrophoresis, Capillary; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2009 |
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Movement Disorders; Neuropsychological Tests; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2010 |
5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.
Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans; Middle Aged; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Tryptophan Hydroxylase; Young Adult | 2009 |
Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study.
Topics: Adult; Aged; Antidepressive Agents; Biomarkers; Citalopram; Depression; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors; Treatment Outcome | 2009 |
Depletion of selective serotonin reuptake inhibitors during sewage sludge composting.
Topics: Bacteria, Aerobic; Biodegradation, Environmental; Bioreactors; Chromatography, High Pressure Liquid; Citalopram; Fluoxetine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sewage; Soil Pollutants; Waste Disposal, Fluid | 2009 |
The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Topics: Adolescent; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Fluoxetine; Humans; Male; Multicenter Studies as Topic; Paroxetine; Personality Assessment; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Deaths involving serotonergic drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Australia; Cause of Death; Citalopram; Cyclohexanols; Female; Fluoxetine; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Serotonin Agents; Sertraline; Tramadol; Venlafaxine Hydrochloride | 2010 |
Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Cohort Studies; Cross-Sectional Studies; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide; Suicide Prevention; Suicide, Attempted | 2010 |
Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
Topics: Adult; Aged; Antidepressive Agents; British Columbia; Cause of Death; Citalopram; Cohort Studies; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Hospitalization; Humans; Male; Middle Aged; Paroxetine; Proportional Hazards Models; Risk; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide, Attempted | 2010 |
Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Citalopram; Cost of Illness; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Placebos; Psychiatric Status Rating Scales; Quality of Life; Randomized Controlled Trials as Topic; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2010 |
Nitric oxide is involved in the regulation of marble-burying behavior.
Topics: Agmatine; Animals; Arginine; Behavior, Animal; Citalopram; Imidazoles; Indazoles; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type I; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2010 |
Defense style in panic disorder before and after pharmacological treatment.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety; Checklist; Citalopram; Defense Mechanisms; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Panic Disorder; Paroxetine; Psychiatric Status Rating Scales; Surveys and Questionnaires | 2011 |
Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective 5-HT reuptake inhibitors on 5-HT release.
Topics: Action Potentials; Animals; Antidepressive Agents; Autoreceptors; Brain; Calcium; Citalopram; Extracellular Space; Fluoxetine; Hydroxyindoleacetic Acid; Organ Culture Techniques; Paroxetine; Raphe Nuclei; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tryptophan Hydroxylase | 2010 |
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Data Collection; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Fatigue; Fluvoxamine; Humans; Internet; Lethargy; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Stages; Thiophenes; Venlafaxine Hydrochloride | 2011 |
Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats.
Topics: Analysis of Variance; Animals; Citalopram; Electroencephalography; Epilepsy; Fluoxetine; gamma-Aminobutyric Acid; Hippocampus; Male; Neural Inhibition; Neurons; Paroxetine; Pilocarpine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Vesicular Inhibitory Amino Acid Transport Proteins | 2010 |
Comment on "Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease".
Topics: Animals; Anti-Inflammatory Agents; Brain; Citalopram; Encephalitis; Humans; Inflammation; Lipopolysaccharides; Mice; Nerve Degeneration; Neurons; Oxidative Stress; Parkinsonian Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2010 |
Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal; Citalopram; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Female; Hot Flashes; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen | 2011 |
Antidepressant use during pregnancy. FPIN’s clinical inquiries.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Evidence-Based Medicine; Female; Fluoxetine; Humans; Odds Ratio; Paroxetine; Physicians, Family; Pregnancy; Pregnancy Complications; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2011 |
Association between tryptophan hydroxylase-2 genotype and the antidepressant effect of citalopram and paroxetine on immobility time in the forced swim test in mice.
Topics: Alleles; Animals; Antidepressive Agents, Second-Generation; Citalopram; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred C57BL; Motor Activity; Paroxetine; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Swimming; Tryptophan Hydroxylase | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Canada; Citalopram; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Heart Failure; Hemorrhage; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Neoplasms; Paroxetine; Peptic Ulcer; Platelet Aggregation Inhibitors; Renal Insufficiency; Retrospective Studies; Risk; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Ticlopidine | 2011 |
The MMPI-2 neurotic triad subscales and depression levels after pharmacological treatment in patients with depressive disorders - clinical study.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Fluoxetine; Humans; Hypochondriasis; Hysteria; Male; Middle Aged; MMPI; Neurotic Disorders; Observer Variation; Paroxetine; Psychometrics; Reproducibility of Results; Sertraline; Statistics as Topic; Young Adult | 2011 |
Angular cheilitis after paroxetine treatment.
Topics: Adult; Anxiety Disorders; Cheilitis; Citalopram; Diagnosis, Differential; Drug Eruptions; Drug Substitution; Female; Follow-Up Studies; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2012 |
The SSRI citalopram affects fetal thalamic axon responsiveness to netrin-1 in vitro independently of SERT antagonism.
Topics: Animals; Axons; Citalopram; Coculture Techniques; Female; Fetus; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Transgenic; Nerve Growth Factors; Netrin-1; Paroxetine; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sigma-1 Receptor; Thalamus; Tumor Suppressor Proteins | 2012 |
Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Citalopram; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Israel; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paroxetine; Patient Selection; Personality Assessment; Predictive Value of Tests; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2012 |
Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Platelets; Case-Control Studies; Citalopram; Down-Regulation; Female; Humans; Male; Middle Aged; Netherlands; P-Selectin; Paroxetine; Platelet Function Tests; Selective Serotonin Reuptake Inhibitors; Serotonin | 2012 |
Interaction of morphine and selective serotonin receptor inhibitors in rats experiencing inflammatory pain.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Citalopram; Disease Models, Animal; Hyperalgesia; Inflammation; Injections, Spinal; Male; Morphine; Pain; Pain Measurement; Pain Threshold; Paroxetine; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Temperature; Time Factors | 2012 |
Comparison of two extraction methods for the determination of selective serotonin reuptake inhibitors in sewage sludge by hollow fiber liquid-phase microextraction.
Topics: Chromatography, Liquid; Citalopram; Fluoxetine; Liquid Phase Microextraction; Mass Spectrometry; Paroxetine; Porosity; Selective Serotonin Reuptake Inhibitors; Sertraline; Sewage; Surface Properties | 2012 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2012 |
Antidepressants inhibit DNA methyltransferase 1 through reducing G9a levels.
Topics: Animals; Antidepressive Agents; Astrocytes; Carbamazepine; Cells, Cultured; Cerebral Cortex; Citalopram; Cyclohexanols; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Glycolipids; Histone-Lysine N-Methyltransferase; Imipramine; Indoles; Maleimides; Mice; Nerve Tissue Proteins; Neural Stem Cells; Neurons; Paroxetine; Protein Interaction Mapping; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Venlafaxine Hydrochloride | 2012 |
A novel spirocyclic tropanyl-Δ²-isoxazoline derivative enhances citalopram and paroxetine binding to serotonin transporters as well as serotonin uptake.
Topics: Animals; Binding Sites; Cerebral Cortex; Citalopram; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Isoxazoles; Molecular Structure; Paroxetine; Rats; Serotonin; Serotonin Plasma Membrane Transport Proteins; Spiro Compounds; Structure-Activity Relationship; Synaptosomes | 2012 |
Fluoxetine suppresses synaptically induced [Ca²⁺]i spikes and excitotoxicity in cultured rat hippocampal neurons.
Topics: Animals; Calcium Channel Blockers; Calcium Signaling; Cell Death; Cells, Cultured; Citalopram; Excitatory Amino Acid Agonists; Exocytosis; Female; Fluoxetine; Hippocampus; Magnesium Deficiency; Neurons; Neuroprotective Agents; Neurotransmitter Agents; p-Chloroamphetamine; Paroxetine; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Synapses | 2013 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagonists; Anxiety Disorders; Citalopram; Clinical Trials, Phase II as Topic; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Multicenter Studies as Topic; Paroxetine; Pyrrolidines; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Young Adult | 2012 |
The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes.
Topics: Astrocytes; Cell Line, Tumor; Citalopram; Fluoxetine; Glioma; Humans; Imidazoles; p38 Mitogen-Activated Protein Kinases; Paroxetine; Pyridines; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tumor Necrosis Factor-alpha | 2013 |
The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents; Canada; Child; Child, Preschool; Citalopram; Databases, Factual; Fluoxetine; Fluvoxamine; Humans; Infant; Mental Disorders; Paroxetine; Practice Patterns, Physicians'; Selective Serotonin Reuptake Inhibitors; Sertraline | 2013 |
Comparison of escitalopram and paroxetine in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Single-Blind Method; Treatment Outcome | 2013 |
Relationship between SSRI-induced sexual dysfunction and central serotonergic activity based on the loudness dependence of auditory evoked potentials.
Topics: Acoustic Stimulation; Adult; Brain; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Hypnotics and Sedatives; Loudness Perception; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Sexual Dysfunction, Physiological | 2014 |
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2014 |
Effects of antidepressant drugs on synaptic protein levels and dendritic outgrowth in hippocampal neuronal cultures.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cell Enlargement; Cells, Cultured; Citalopram; Dendrites; Fluoxetine; Hippocampus; Imipramine; Nerve Tissue Proteins; Neurons; Paroxetine; Rats; Rats, Sprague-Dawley; Sertraline; Thiazepines; Tranylcypromine | 2014 |
Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
Topics: 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Benzofurans; Brain; Citalopram; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Fluoxetine; Indoles; Male; Paroxetine; Piperazines; Pyridines; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Vilazodone Hydrochloride | 2014 |
Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Prospective Studies; Recurrence; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2015 |
Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Child; Citalopram; Databases, Factual; Drug Monitoring; Drug Utilization; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Norway; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Young Adult | 2015 |
Serotonin syndrome following metaxalone overdose and therapeutic use of a selective serotonin reuptake inhibitor.
Topics: Adult; Citalopram; Drug Interactions; Drug Overdose; Female; Humans; Male; Neuromuscular Agents; Oxazolidinones; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Treatment Outcome | 2015 |
Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
Topics: Adult; Asia, Eastern; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Pain; Paroxetine; Prospective Studies; Quality of Life; Regression Analysis; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Severity of Illness Index; Treatment Outcome | 2016 |
Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors' Behavioral and Neurochemical Effects.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Antidepressive Agents; Brain; Citalopram; Cyclic AMP Response Element-Binding Protein; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Female; Histamine; Histidine Decarboxylase; Male; Methylhistidines; Methysergide; Mice, Knockout; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2015 |
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Moclobemide; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2015 |
Dry Eye Related to Commonly Used New Antidepressants.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Case-Control Studies; Citalopram; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2015 |
Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay.
Topics: Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Citalopram; Estradiol; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Progesterone; Selective Serotonin Reuptake Inhibitors; Sertraline; Testosterone | 2015 |
Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs.
Topics: Analgesics; Antidepressive Agents; Citalopram; Dose-Response Relationship, Drug; Fluoxetine; HEK293 Cells; Humans; Membrane Potentials; Moclobemide; Monoamine Oxidase Inhibitors; NAV1.7 Voltage-Gated Sodium Channel; NAV1.8 Voltage-Gated Sodium Channel; Paroxetine; Patch-Clamp Techniques; Selective Serotonin Reuptake Inhibitors; Sodium Channel Blockers; Time Factors; Transfection | 2015 |
Topiramate augmentation in a patient with obsessive-compulsive disorder.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Citalopram; Drug Synergism; Fear; Female; Fructose; Humans; Lorazepam; Obsessive-Compulsive Disorder; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Sertraline; Topiramate; Treatment Refusal | 2015 |
Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Citalopram; Cyclopropanes; Duloxetine Hydrochloride; Fluvoxamine; Hep G2 Cells; Humans; Liver Neoplasms; Milnacipran; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline | 2015 |
Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Child, Preschool; Citalopram; Cohort Studies; Databases, Factual; Depression; Dose-Response Relationship, Drug; Drug Labeling; Drug Prescriptions; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Practice Guidelines as Topic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Suicide, Attempted; United States; United States Food and Drug Administration; Young Adult | 2016 |
Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats.
Topics: Animals; Antidepressive Agents; Brain; Citalopram; Male; Paroxetine; Rats; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sexual Behavior; Vilazodone Hydrochloride | 2016 |
X-ray structures and mechanism of the human serotonin transporter.
Topics: Allosteric Regulation; Allosteric Site; Antidepressive Agents; Citalopram; Crystallography, X-Ray; Dopamine Plasma Membrane Transport Proteins; Drug Design; Extracellular Space; Humans; Immunoglobulin Fab Fragments; Intracellular Space; Ions; Ligands; Models, Molecular; Paroxetine; Protein Binding; Protein Conformation; Protein Stability; Serotonin; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2016 |
Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB.
Topics: Adult; Benzylamines; Brain; Carbon Radioisotopes; Citalopram; Dose-Response Relationship, Drug; Female; Humans; Male; Paroxetine; Positron-Emission Tomography; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline; Young Adult | 2016 |
Differential Associations of Specific Selective Serotonin Reuptake Inhibitors With Resting-State Heart Rate and Heart Rate Variability: Implications for Health and Well-Being.
Topics: Adult; Aged; Brazil; Citalopram; Electrocardiography; Female; Fluoxetine; Heart Rate; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2016 |
A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors.
Topics: Adult; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2016 |
Effect of antidepressants on spatial memory deficit induced by dizocilpine.
Topics: Animals; Antidepressive Agents; Cell Count; Citalopram; Cognition; Cognitive Dysfunction; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Fluvoxamine; Hippocampus; Interneurons; Male; Maze Learning; Memory Disorders; Mianserin; Mirtazapine; Paroxetine; Rats; Rats, Sprague-Dawley; Schizophrenia; Schizophrenic Psychology; Sertraline; Spatial Memory; Venlafaxine Hydrochloride | 2016 |
Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications.
Topics: Child; Child, Preschool; Citalopram; Coma; Dose-Response Relationship, Drug; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Hospitalization; Humans; Infant; Male; Paroxetine; Poison Control Centers; Retrospective Studies; Seizures; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Vilazodone Hydrochloride | 2017 |
Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition.
Topics: Adult; Antidepressive Agents; Citalopram; Databases, Factual; Depressive Disorder; Drug Monitoring; Female; Fluvoxamine; Humans; Norway; Paroxetine; Pregnancy; Pregnancy Trimester, Third; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2017 |
A comparative study of QT prolongation with serotonin reuptake inhibitors.
Topics: Adult; Aged; Arrhythmias, Cardiac; Citalopram; Databases, Factual; Female; Fluvoxamine; Humans; Long QT Syndrome; Male; Middle Aged; Paroxetine; Pharmacovigilance; Selective Serotonin Reuptake Inhibitors; Sertraline | 2017 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2017 |
Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function.
Topics: Animals; Citalopram; Depression; Fluoxetine; Hindlimb Suspension; Male; Mice, Inbred C57BL; Mice, Inbred DBA; Paroxetine; Protein Binding; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Species Specificity; Swimming; Synaptosomes | 2017 |
Study of the link between dopamine transporter gene polymorphisms and response to paroxetin and escitalopram in patients with lifelong premature ejaculation.
Topics: Adult; Citalopram; Dopamine Plasma Membrane Transport Proteins; Ejaculation; Humans; Male; Middle Aged; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Premature Ejaculation; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2017 |
Mapping the Binding Site for Escitalopram and Paroxetine in the Human Serotonin Transporter Using Genetically Encoded Photo-Cross-Linkers.
Topics: Binding Sites; Citalopram; Crystallography, X-Ray; Humans; Models, Molecular; Paroxetine; Protein Binding; Protein Conformation; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2017 |
Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression.
Topics: Citalopram; Depressive Disorder, Major; Humans; Paroxetine; Placebo Effect; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors | 2018 |
Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.
Topics: Aged; Aged, 80 and over; Citalopram; Cohort Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metoprolol; Middle Aged; Mirtazapine; Netherlands; Paroxetine | 2018 |
Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
Topics: Altitude Sickness; Animals; Antidepressive Agents; Brain; Citalopram; Dopamine; Female; Fluoxetine; Male; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 2018 |
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pharmacoepidemiology; Sertraline; United States; Venlafaxine Hydrochloride | 2018 |
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Citalopram; Epithelial Cells; Fluoxetine; Paroxetine; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Sertraline; Swine | 2018 |
Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
Topics: Activities of Daily Living; Adult; Aged; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychometrics; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Vortioxetine | 2019 |
Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Topics: Adolescent; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Monte Carlo Method; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2019 |
A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression.
Topics: Adult; Aged; Aged, 80 and over; Animals; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Receptors, Serotonin; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Young Adult | 2020 |
Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence.
Topics: Citalopram; Databases, Factual; Drugs, Generic; Humans; Paroxetine; Practice Patterns, Physicians'; Prescription Fees; Scotland; Selective Serotonin Reuptake Inhibitors; Sertraline; State Medicine | 2019 |
Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Longitudinal Studies; Outcome Assessment, Health Care; Paroxetine; Placebos; Psychiatric Status Rating Scales; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index | 2019 |
Serotonin and serotonin reuptake inhibitors alter placental aromatase.
Topics: Aromatase; Cells, Cultured; Citalopram; Female; Fluoxetine; Humans; Molecular Docking Simulation; Paroxetine; Placenta; Pregnancy; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Trophoblasts; Venlafaxine Hydrochloride | 2019 |
Combining threshold analysis and GRADE to assess sensitivity to bias in antidepressant treatment recommendations adjusted for depression severity.
Topics: Acetamides; Adult; Amitriptyline; Antidepressive Agents; Bayes Theorem; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Network Meta-Analysis; Paroxetine; Publication Bias; Reproducibility of Results; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Using filled prescription sequences to rank antidepressants according to their acceptability in the general population: The Constances cohort.
Topics: Antidepressive Agents; Citalopram; Female; Humans; Male; Middle Aged; Paroxetine; Prescriptions; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2020 |
The teratogenic effects of sertraline in mice.
Topics: Animals; Citalopram; Female; Humans; Mice; Mice, Inbred ICR; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors; Sertraline | 2020 |
Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
Topics: Antidepressive Agents; Anxiety; Citalopram; Depressive Disorder, Major; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Least-Squares Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2020 |
Low SSRI dosing in clinical practice-a register-based longitudinal study.
Topics: Child; Citalopram; Fluoxetine; Humans; Longitudinal Studies; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2021 |
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Topics: Antidepressive Agents; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P450 Family 2; Drug Interactions; Humans; Paroxetine; Pharmacogenetics; Selective Serotonin Reuptake Inhibitors; Sertraline | 2022 |
Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Humans; Italy; Paroxetine; Retrospective Studies; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo.
Topics: Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2022 |
Antidepressants Are Poor Inhibitors of Heat-Evoked Ion Currents Mediated by TRPM2.
Topics: Adenosine Diphosphate Ribose; Amitriptyline; Animals; Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Fluoxetine; HEK293 Cells; Hot Temperature; Humans; Ketamine; Lidocaine; Mice; Paroxetine; Pregabalin; Sertraline; TRPM Cation Channels | 2022 |
Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice.
Topics: Animals; Anxiety; Citalopram; Male; Mice; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2022 |
SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila.
Topics: Animals; Antidepressive Agents; Citalopram; Drosophila; Drosophila melanogaster; Fluoxetine; Mammals; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin | 2022 |
The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.
Topics: Case-Control Studies; Citalopram; Cohort Studies; Death, Sudden, Cardiac; Dialysis Solutions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Potassium; Renal Dialysis; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2022 |
Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Topics: Body Weight; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Fluoxetine; Humans; Paroxetine; Phenotype; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2022 |
Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths.
Topics: Adolescent; Antipsychotic Agents; Citalopram; Diabetes Mellitus, Type 2; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2022 |
Using filled prescription sequences to rank antidepressants: A nationwide replication study.
Topics: Antidepressive Agents; Citalopram; Fluoxetine; Humans; Paroxetine; Venlafaxine Hydrochloride | 2023 |